Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. - Wikidata - awgldk - TriplyDB

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

http://www.wikidata.org/entity/Q37240622

about

Epidemiology and clinical course of Crohn's disease: results from observational studies Adverse effects of biologics: a network meta-analysis and Cochrane overview Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease Thalidomide and thalidomide analogues for induction of remission in Crohn's disease Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease Inflammatory bowel disease surgery in the biologic era Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Diagnostic imaging advances in murine models of colitis.Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Current stage in inflammatory bowel disease: What is next?Pharmacologic therapy for inflammatory bowel disease refractory to steroids Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies Inflammatory pathways of importance for management of inflammatory bowel disease Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease Use of the tumor necrosis factor-blockers for Crohn's disease THERAPIES FOR CROHN'S DISEASE: a clinical update The Role of Laboratory Tests in Crohn's Disease Current therapy of pediatric Crohn's disease Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.Inflammatory bowel disease and celiac disease: overlaps and differences.Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis Use of thiopurines in inflammatory bowel disease: Safety issues.Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.Impact of pain on health-related quality of life in patients with inflammatory bowel disease Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.

P2860

Q22241217-92653856-646D-4E16-A4EB-385DAAD9D21D Q24234197-2F0A2FDF-578B-4466-ADE1-B87CE4E1C110 Q24241489-2D2B45FB-7CA5-4824-98EB-4AA65D09DD2A Q24241766-4F6C0423-420A-4C8B-9750-B1D5E83A86E9 Q24242101-4564828B-3DFC-4867-BE39-465EB0B2BD14 Q26745627-98BD947B-9E8A-49EA-9E15-7841D43562E7 Q26750190-288CBB43-A7AA-408B-B7B4-1010A8923F63 Q26750456-A11B3CAE-F463-47F2-8534-501AD20226B6 Q26774583-87E63BAA-7D02-44FC-AF96-5F8B69E74EF9 Q26775240-6345ED89-0623-402E-A979-9271119B93BE Q26777409-87644B49-EDC2-4FD6-B713-CFB905326FE6 Q26777429-B8B1F8BF-B9E2-4FF6-BE0A-12628CD9A443 Q26796415-A35A1138-19D9-4138-BE8C-42418DB0264C Q26801119-54DCB3F8-883A-4DE0-9945-C8FD547E3428 Q26822029-395B2926-0204-42EE-B537-C4FEE24A41C3 Q26829488-76118739-DA79-4633-8A97-19DBE3DEE34F Q26991673-E098C3DB-CDCA-47FE-95A3-10BEDEC5B344 Q27005445-8AFDC51A-8863-436D-8F95-9B7717915BBD Q27027630-FD43012A-2E44-445F-8F2B-670127DFB0F3 Q27030762-A325C47B-3192-49D5-8C11-5985F553DD70 Q28070271-FAE85140-BC9A-4C88-B48C-3AE22A341C37 Q28075045-02786C47-72B3-4B0C-852D-876AF834FCDF Q28081919-1BD07265-0BA5-42E1-8DC8-FFB6211D7E0A Q28083872-F0FF6CDA-6E59-4CEC-9FB8-8B8AAAD6C9B5 Q30234628-DB75BC2E-1E4F-4EF1-A01A-AAB3DB1D84BE Q30242073-0BBD9C64-FC5C-4FA4-885B-EAF585EB98D3 Q30679247-AACE2CF1-6D71-4721-98C1-A4CBCAB0D5C1 Q33362566-9ADCC73F-4B64-4ABD-82F6-043E4827552D Q33562796-E5632A2D-0B53-47E5-9425-09EE5782BC6C Q33564085-296D92FD-E751-422E-BEB0-3ECD0AE52BF0 Q33564492-3B767611-215D-4990-8403-6E7E1561FE0B Q33621267-44A56157-2EBB-4B87-B702-D3B66948F2E5 Q33667897-B21B67D4-0131-4F27-8364-3B24014C797E Q33711741-66FD7294-4ACA-4571-8A7F-5BC69B505D19 Q33756929-79134E53-9EDD-4155-9B42-58B392349B66 Q33874790-E34A8202-C39C-4F6E-A643-6FD6788F9278 Q33933336-4BC1C4EE-1E7B-44F4-964E-8C7C8E54F5E9 Q33960394-BCACAE2B-3013-4278-B0D3-EB9879A6F5AD Q34050113-383FF44C-3871-4A7B-B781-CA8A227A35ED Q34100121-99143100-AE59-4103-876B-9CD2571E92B7

P2860

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

http://www.wikidata.org/entity/Q37240622

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 February 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

@en

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

@nl

type

label

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

@en

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

@nl

prefLabel

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

@en

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

@nl

P1433

Q37240622-BAE91675-A530-407A-B417-F856CFBC30A7

P1476

Q37240622-FFE267C2-F6E8-49F5-A456-71EFBDCF9A33

P2093

Q37240622-13D4D06A-8B41-4D2F-B202-C962F653DD14

Q37240622-20D271FB-204C-4BD8-86F0-416E382742E0

Q37240622-257DA9E7-89B3-4D95-B845-8B3979FFD190

Q37240622-3A923AD2-B279-433B-880D-F5F0488D952C

Q37240622-4E4B77F2-325D-42B6-99C1-9BC42CB85892

Q37240622-74DCE0DE-6F12-4F87-B606-814CFA1D8454

Q37240622-76F163F3-E612-4C24-BE4D-725635EB0E06

Q37240622-7AF50C46-E448-4E85-9280-367D31520105

Q37240622-D5D2EE71-1C04-43FE-9E01-35FD4BE22156

Q37240622-F1FF8398-A1A1-4E60-A21B-2B34FE213109

P2860

Q37240622-01BD7A4C-D4A6-4A42-B59E-02C1A8223E96

Q37240622-0B479891-58FD-4296-99AC-C98B4C45E10B

Q37240622-0F627C2E-367C-4A81-A675-CE9A15DC8CDB

Q37240622-110A6942-259E-4E2C-BE37-019EA88BC998

Q37240622-1D582924-4076-4CD2-8A6A-B8ECA1B551AE

Q37240622-1F1B73B6-F2D1-4311-BEB5-B20CC84907E2

Q37240622-2FC2B812-12BC-470C-9061-7D1AE2463201

Q37240622-34A03F27-3079-4273-8AF2-29E8EB82110D

Q37240622-3B101440-C42F-4D3D-B643-6E21B07EB4B0

Q37240622-52DF5BBD-8BB7-4C08-9F5E-4D11128FCCE3

P304

Q37240622-3D042CE4-E268-41B5-841C-0955123A756D

P31

Q37240622-85027040-4057-4657-9930-DA1E08A1295C

P356

Q37240622-237C100A-D481-4040-9561-FFEEE6D3DE81

P407

Q37240622-6F16A5E2-0885-40B7-8762-F1B5331C6C8F

P433

Q37240622-A7D43177-1C50-46C8-8909-87691FC9781E

P478

Q37240622-EBFFBB8C-E30C-4D0D-B922-D213168106F7

P50

Q37240622-1BD68CA3-6D59-4390-BB5E-EE9CA2891892

Q37240622-270DBBEB-E624-4419-8BBB-432596BD51E5

P577

Q37240622-0029D1A6-FA1E-4F3B-AFFB-350318F833B1

P5875

Q37240622-96655706-B7C0-4813-868A-6F0F4A1D5B81

P698

Q37240622-F38318F8-118B-4F9C-AC65-A271CB1E9261

P921

Q37240622-81DBB8FA-E614-4886-BDAB-A24F9EAF0467

Q37240622-D2A2E8EB-7E23-4E09-8E1B-CB597E409FDC

P932

Q37240622-425ADAB1-2DDE-406D-A8F6-F6FA778F7055

P356

GUT.2006.106781

P1433

P1476

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

@en

P2093

B Bittle

http://www.w3.org/2001/XMLSchema#string

D G MacIntosh

http://www.w3.org/2001/XMLSchema#string

D Wolf

http://www.w3.org/2001/XMLSchema#string

J D Kent

http://www.w3.org/2001/XMLSchema#string

J Li

http://www.w3.org/2001/XMLSchema#string

P F Pollack

http://www.w3.org/2001/XMLSchema#string

P Rutgeerts

http://www.w3.org/2001/XMLSchema#string

R Panaccione

http://www.w3.org/2001/XMLSchema#string

S B Hanauer

http://www.w3.org/2001/XMLSchema#string

W J Sandborn

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic monoclonal antibodies

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

Infliximab maintenance therapy for fistulizing Crohn's disease

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Tumor necrosis factor: biology and therapeutic inhibitors.

P304

1232-1239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2006.106781

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Richard N. Fedorak

P577

2007-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6506463

http://www.w3.org/2001/XMLSchema#string

P698

17299059

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

2701613

http://www.w3.org/2001/XMLSchema#string